๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kolkata
Clinical trial register · India

Clinical Trials in Kolkata, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 335 Mumbai 261 Hyderabad 238 Bangalore 199 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca54 Bristol-Myers Squibb12 Janssen Research & Development, LLC11 Pfizer10 Novartis Pharmaceuticals6
Site location
New Delhi335 Mumbai261 Hyderabad238 Bangalore199 Pune189
All 275 locations
Target enrolment
to

Trials with a site in Kolkata

168 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Belagavi, Nagpur, Pune, New Delhi, Dehradun, Kolkata, Ahemdabad, Bangalore
2026-12-16
Not yet open
Development and Validation of the Indian Asthma Care Bundle for Reducing Readmission and Improving Post-hospitalisation Care After Discharge From Hospital Due to an Acute Asthma Exacerbation
NCT07815730Asthma Exacerbation, Asthma (Diagnosis), Exacerbations, Hospitalisation
Ahmedabad University
Not applicable
260
Delhi, Kolkata
2026-12-01
Not yet open
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
NCT07838155Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 4
50
Bangalore, Kolkata, Mumbai, New Delhi, Tamil Nadu, Vellore
2026-10
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Belgavi, Kozhikode, Nashik, Sakri, Kolkata, Nagpur, New Delhi
2026-09-11
Not yet open
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Kolkata
2026-09-01
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
DrugAZD6234
AstraZeneca
Phase 3
1,500
Bangalore, Indore, Kolkata, Nagpur, Pune, Siliguri, Visakhapatnam
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugAZD6234
AstraZeneca
Phase 3
2,500
Bhubaneswar, Coimbatore, Hyderabad, Indore, Jaipur, Jodhpur, Kochi, Kolkata
2026-08-19
Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613Diabetes Mellitus, Type 2
DrugCagriSema
Novo Nordisk A/S
Phase 3
80
Guntur, Surat, Bangalore, New Delhi, Delhi, Kanpur, Kolkata, Kolhฤpur
2026-08-04
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Datopotamab Deruxtecan·Opdivo
AstraZeneca
Phase 3
915
Kolkata, Kottayam, Nashik, Navi Mumbai, New Delhi
2026-07-16
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
NCT07613307Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
DrugOrforglipron
Eli Lilly and Company
Phase 3
130
Agra, Hyderabad, Kanpur, Kolkata, Mumbai, Mysore, Nashik, Nellore
2026-07-15
Recruiting
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
NCT07661329Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
YS Life Science Co., Ltd.
Phase 3
600
Ahmedabad, Nagpur, Nerul, Bhubaneswar, Kolkata
2026-06-02
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsJNJ-79635322·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Bengaluru, Gurgaon, Jaipur, Kolkata, New Delhi, Pune
2026-05-31
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Aurangabad, Pune, Rishikesh, Kolkata, Delhi
2026-05-27
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Belagavi, Kochi, Ludhiana, Kolkata, New Delhi
2026-05-17
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
Kochi, Kolkata, Maharashtra, New Delhi
2026-04-20
Recruiting
Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis
NCT07441824Acute Necrotizing Pancreatitis, Pancreatic Exocrine Insufficiency
Asian Institute of Gastroenterology, India
Phase 3
140
Guwahati, Hyderabad, Kolkata
2026-04-10
Recruiting
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
NCT07169695Moderate to Severe Vernal Keratoconjunctivitis
DrugCiclosporin
Laboratoires Thea
Phase 2
120
Kolkata, Ahmedabad, Bangalore, Hyderabad, Jaipur, Patna, Pune, Surat
2026-03-24
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mohali, Mumbai, New Delhi, Varanasi
2026-02-03
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
Guntur, Surat, Bangalore, New Delhi, Delhi, Kanpur, Kolkata, Kolhฤpur
2026-01-08
Active, closed
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
NCT07455097Intermediate-risk Prostate Cancer, High-risk Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
600
Kolkata
2026-01-01
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhฤpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Chennai, Jaipur, Kolkata, Nashik, New Delhi, Vadodara
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Ahmedabad, Hyderabad, Varanasi, Kolkata, Delhi, New Delhi
2025-12-02
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Ahmedabad, New Delhi, Coimbatore, Kolkata
2025-11-19
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab Deruxtecan·Docetaxel
AstraZeneca
Phase 3
400
Bangalore, Kolkata, Mumbai, Nashik, New Delhi
2025-10-31
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Aligarh, Jaipur, Kolkata, Kozhikode, Nagpur, Nashik, New Delhi, Rishikesh
2025-10-31
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Kochi, Mumbai, New Delhi, Bhubaneswar, Hyderabad, Varanasi, Kolkata
2025-10-23
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Ahmedabad, Bhubaneswar, Chandigarh, Ernฤkulam, Hyderabad, Jaipur, Kochi, Kolkata
2025-10-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
DrugKarXT
Bristol-Myers Squibb
Phase 3
424
Mangalore, Madurai, Kolkata
2025-10-08
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
Mumbai, New Delhi, Jaipur, Kolkata
2025-10-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Hyderabad, Rajkot, Nagpur, Jaipur, Kolkata
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
DrugsPF-08046054·Docetaxel
Pfizer
Phase 3
680
Mumbai, Pune, New Delhi, Kolkata, Delhi, Kerala
2025-09-29
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Active, closed
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
NCT07109297RSV Immunization
DrugNirsevimab
Sanofi
Phase 4
110
Bengaluru, Jaipur, Kolkata, Nagpur, New Delhi, Pune, Vizianagaram
2025-07-31
Recruiting
Left Bundle Branch Area Pacing (LBBAP) PMCF Study
NCT07217392Bradycardia, Right Ventricular Pacing, Heart Failure, Atrial Fibrillation (AF)
Abbott Medical Devices
Not applicable
200
Bangalore, New Delhi, Madurai, Kolkata
2025-07-24
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Ahmedabad, Bengaluru, Bikaner, Kanpur, Kolkata, Maharashtra, Nagpur, Nashik
2025-07-22
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
DrugsValproate·Lamotrigine·Lithium·KarXT
Bristol-Myers Squibb
Phase 3
450
Vadodara, Belagavi, Mangalore, Kozhikode, Ludhiana, Madurai, Hyderabad, Kolkata
2025-07-18
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Bengaluru, Hyderabad, Varanasi, Kolkata
2025-07-14
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Ahmedabad, Hyderabad, Varanasi, Kolkata, Delhi, New Delhi
2025-07-10
Recruiting
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
NCT06862219Metastatic Urothelial Carcinoma
DrugEnfortumab Vedotin
Astellas Pharma Global Development, Inc.
Phase 4
100
Patna, Kochi, Mumbai, New Delhi, Dumas, Vellore, Varanasi, Kolkata
2025-06-21
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
DrugKarXT
Bristol-Myers Squibb
Phase 3
274
Vadodara, Belagavi, Kozhikode, Ludhiana, Hyderabad, Kolkata
2025-06-13
Active, closed
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517Multiple Myeloma
DrugTeclistamab
Johnson & Johnson Private Limited
Phase 4
75
Bangalore, Bengaluru, Chandigarh, Jaipur, Kolkata, Mumbai, Nagpur, New Delhi
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Hyderabad, Bangalore, Pune, New Delhi, Lucknow, Varanasi, Kolkata, Chandigarh
2025-05-22
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
Aurangabad, Bangalore, Bikaner, Chennai, Kochi, Kolkata, Nashik, New Delhi
2025-05-20
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Ahmedabad, Ernฤkulam, Mumbai, New Delhi, Ludhiana, Vellore, Ghaziabad, Kolkata
2025-05-06
Recruiting
Measuring Ultrasound Guided Skeletal Muscle Mass of Lower Extremity as a Predictor of Post-Operative Length of Stay in Exploratory Gynae-oncology Surgeries
NCT06816836Gynecologic Cancer, Frailty, Sarcopenia
Tata Medical Center
Observational
320
Kolkata
2025-04-01
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
DrugSAR441566
Sanofi
Phase 2
204
Hyderabad, Jaipur, Kolkata, Ludhiana, Secunderabad, Surat, Visakhapatnam
2025-03-28
Recruiting
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
NCT06368245Spinal Fusion
AO Foundation, AO Spine
Observational
1,244
Kolkata
2025-03-24
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Keytruda·Pemetrexed·Paclitaxel
Immutep S.A.S.
Phase 3
756
Bangalore, Bhubaneswar, Chennai, Kolkata, New Delhi, Thane, Thiruvananthapuram, Varanasi
2025-03-21
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Ahmedabad, Kolkata, Mumbai, Nagpur, Nashik, Pune, Vadodara, Varanasi
2025-03-19
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Adrucil·Trastuzumab
AstraZeneca
Phase 3
840
Ansฤrinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Recruiting
Effects of Advanced Trauma Life Supportยฎ on Adult Trauma Patient Outcomes
NCT06321419Wounds and Injuries
Karolinska Institutet
Not applicable
4,320
Dibrugarh, Mumbai, New Delhi, Ludhiana, Dehradun, Kolkata, Chandigarh
2025-02-27
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Bengaluru, New Delhi, Madurai, Varanasi, Kolkata
2025-02-25
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naรฏve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi, Noida
2025-02-21
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Ahmedabad, Bhubaneswar, Hubballi, Kolkata, Mysuru, New Delhi, Noida, Surat
2025-01-09
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Ahmedabad, Bangalore, Hyderabad, Kolkata, Pune, Sushrut Hospital and Research
2024-12-16
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Adrucil·Cetuximab
Janssen Research & Development, LLC
Phase 3
700
Delhi, Hyderabad, Kolkata, Mumbai, New Delhi, Pune, Varanasi, Vellore
2024-12-12
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
DrugSAR441566
Sanofi
Phase 2
260
Hyderabad, Jaipur, Kolkata, Pune, Secunderabad, Surat
2024-12-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Ahmedabad, Kolkata, Miraj, Mumbai, Varanasi
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gurgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-18
Recruiting
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
NCT06666491Malaria, Vivax
DrugsChloroquine·Primaquine·Tafenoquine
GlaxoSmithKline
Phase 3
300
Ahmedabad, Kolkata, Mumbai, Surat
2024-11-13
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Adrucil
Janssen Research & Development, LLC
Phase 3
1,000
Delhi, Kolkata, Mumbai, Pune, Varanasi
2024-10-18
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Aurangabad, Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2024-09-26
Recruiting
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
NCT06462235Gram-negative Bacterial Infection
Pfizer
Phase 2
48
Surat, Bengaluru, Pune, Lucknow, Kolkata
2024-09-25
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
2024-08-12
Not yet open
Trial Comparing Avg. Global Qual of Lifescore in Hypo Frac. RT vs Conv. Frac. in H&N Cancers
NCT06536699Radiation Treatment
Tata Medical Center
Not applicable
600
Kolkata
2024-08-07
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Ahmedabad, Bangalore, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow
2024-06-20
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Ahmedabad, Belagavi, Chandigarh, Faridabad, Kolkata, Nagpur, Pune
2024-05-08
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab Deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
NCT05983471Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
Melius Pharma AB
Phase 2
40
Guntur, Belagavi, Pune, Coimbatore, Kanpur, Kolkata
2024-04-01
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Dehradun, Hyderabad, Kolkata
2024-03-29
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Guwahati, Allahฤbฤd, Kolkata, Bhubaneswar, Gujrฤt, Nagpur, New Delhi, Surat
2024-03-13
Recruiting
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
NCT06189209Triple Negative Breast Cancer (TNBC)
Rhizen Pharmaceuticals SA
Phase 2
40
Vijayawada, Bangalore, Mumbai, Pune, Madurai, Hyderabad, Kolkata
2024-03-04
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Hyderabad, Bangalore, Mumbai, Pune, New Delhi, Bhubaneswar, Chennai, Kolkata
2024-02-28
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Bangalore, Haryฤna, Hyderabad, Kolkata, New Delhi, Pune, Thiruvananthapuram
2024-02-05
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Bengaluru, Hyderabad, Jaipur, Kanpur, Kochi, Kolkata, Lucknow, Madurai
2023-12-14
Active, closed
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
NCT07052006Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
Halia Therapeutics, Inc.
Phase 2
37
Ahmedabad, Kannur, Visakhapatnam, Kolhฤpur, Dehradun, Madurai, Hyderabad, Kolkata
2023-12-09
Active, closed
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
NCT05653063Cancer of Prostate, Cancer Head Neck, Cancer Cervix
University College, London
Observational
1,029
Kolkata, Mumbai
2023-12-07
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Tislelizumab·Capecitabine
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Calicut, Chennai, Jaipur, Kochi, Kolkata, Kottayam, Marg Jaipur, Mohali
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Abiraterone acetate·Darolutamide·Enzalutamide
AstraZeneca
Phase 3
1,898
Bangalore, Calicut, Kanpur, Kolkata, Nagpur, New Delhi, Pune, Vadodara
2023-11-21
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsXeloda·Epirubicin·Datopotamab Deruxtecan·Olaparib
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Ahmedabad, Delhi, Gurugram, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi
2023-11-08
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Bengaluru, Hyderabad, Kolkata, Mysuru, Nagpur, Varanasi
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Ansฤrinagar, Bangalore, Dehradun, Delhi, Kolkata, Kozhikode, Mumbai, Mysuru
2023-10-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Ahmedabad, Surat, Gurugram, Mumbai, Nagpur, NEW Delhi Delhi, Kolkata
2023-09-08
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2023-07-11
Active, closed
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
451
Ahmedabad, Chennai, Hyderabad, Kolkata, Nagpur, Nashik, New Delhi, Pune
2023-06-26
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Chandigarh, Bangalore, Kochi, Kolhฤpur, Nagpur, Pune, Bhubaneswar, Kolkata
2023-06-22
Active, closed
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (ฮฒ-Thal) in India
NCT05891249Anemia
DrugLuspatercept
Bristol-Myers Squibb
Phase 4
85
Ahmedabad, New Delhi, Kolkata, Assam, Bangalore, Chandigarh, Delhi, Hyderabad
2023-06-05
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Gurugram (Gurgaon), Kochi, Kolkata
2023-05-20
Active, closed
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110Lung Malignancy
AstraZeneca
Observational
712
Gurugram, New Delhi, Hyderabad, Bangalore, Chennai, Kolkata, Mumbai, Pune
2023-04-20
Recruiting
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
NCT05639647Gram-negative Bacterial Infections
Pfizer
Phase 2
48
Bangalore, Lucknow, Kolkata
2023-04-18
Rows per page Showing 1–100 of 168
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/city/kolkata

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 168 of those studies with a site in Kolkata.

How many clinical trials are recruiting in Kolkata?

84 of the 168 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 6 have not yet opened recruitment, 78 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kolkata), 168 studies
PhaseStudiesRecruitingShare
Phase 31196170.8%
Phase 221912.5%
Observational1076%
Not applicable844.8%
Phase 4724.2%
Phase 2/3311.8%

Most active sponsors

Lead sponsors with the most studies (Kolkata)
Lead sponsorStudiesRecruiting
AstraZeneca5422
Bristol-Myers Squibb127
Janssen Research & Development, LLC115
Pfizer107
Novartis Pharmaceuticals62
Sanofi60
Eli Lilly and Company53
Bayer31
Boehringer Ingelheim33
Genzyme, a Sanofi Company33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.